Back to search
FDAFDA · Food and drugs·Recall number D-0065-2023

PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.

Published November 23, 2022 · Recall initiated: November 10, 2022

Summary

FDA records drug Class II recall D-0065-2023, published November 23, 2022 and initiated November 10, 2022. Recalling firm: Nephron Sterile Compounding Center LLC; Status: Terminated; Reported quantity: 56,220 vials; Lot: Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Potential for cross contamination due to product carry over.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nephron Sterile Compounding Center LLC
Distributor
Nationwide in the USA
Lot
Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2. recalled?

Yes. FDA published recall D-0065-2023 on November 23, 2022. Reported hazard: CGMP Deviations: Potential for cross contamination due to product carry over.

What should I do if I have this product?

Voluntary: Firm initiated · Letter